Additionally, tumor-infiltrating immune cells in the tumor environment demonstrate increased levels of PD-L1 expression, and the administration of ICI leads to an enhanced influx of CD8+ T lymphocytes in the tumor region [58]. This evidence concerns the gene CD8A and neoplasm.